Rationale and Design of the ‘MITOCARE’ Study: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRO40303 for the Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction

Publisher： Karger

E-ISSN： 1421-9751|123|4|201-207

ISSN： 0008-6312

Source： Cardiology, Vol.123, Iss.4, 2012-11, pp. : 201-207

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 7, 2015-07 ,pp. : 1703-1710

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial‐onset seizures

By  

EPILEPSIA, Vol. 56, Iss. 12, 2015-12 ,pp. : 1890-1898

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors

By Kellum A.   Jagiello-Gruszfeld A.   Bondarenko I.N.   Patwardhan R.   Messam C.   Mostafa Kamel Y.  

Current Medical Research and Opinion, Vol. 26, Iss. 10, 2010-10 ,pp. : 2339-2346

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Safety of Clopidogrel 600 mg Administered Pre-Hospitally to Improve Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction (CIPAMI): Study Rationale and Design

By  

Cardiology, Vol. 108, Iss. 4, 2006-11 ,pp. : 265-272

Karger

Access to resources Recommend Favorite

Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 17, Iss. 7, 2015-07 ,pp. : 735-742

John Wiley & Sons Inc

Access to resources Recommend Favorite